Shanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's Approval
MT Newswires Live02-06
Shanghai Henlius Biotech's (HKG:2696) serplulimab injection in combination with carboplatin and etoposide has been approved by the European Commission for the first-line treatment of adult patients with extensive-stage small cell lung cancer, a Wednesday bourse filing said.
The injection is an anti-PD-1 monoclonal antibody used for the treatment of various types of lung cancer. It has been approved in mainland China to be used in combination with chemotherapy.
The injection will be deployed in Europe under the trade name Hetronifly. The approval implies a centralized marketing authorization for the injection for all the EU member states together with Iceland, Liechtenstein, and Norway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
